The introduction of biosimilar drugs in the U.S. hands health-care payers a weapon against rising drug prices. In Europe, though, safety concerns and low awareness have slowed the adoption of biosimilars.
from WSJ.com: US Business http://ift.tt/1L4zhwo
via IFTTT
No comments:
Post a Comment